Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Annovis Bio Inc (ANVS)

Annovis Bio Inc (ANVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Annovis to Attend the AAIC 2025 with Four Poster Presentations

ANVS : 2.71 (-4.91%)
Annovis Announces NYSE Acceptance of Plan to Regain Listing Compliance

ANVS : 2.71 (-4.91%)
Annovis to Host Webinar and Live Q&A on June 24, 2025

ANVS : 2.71 (-4.91%)
Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results

ANVS : 2.71 (-4.91%)
Annovis Bio Appoints Hui Liu as Director of Biostatistics

ANVS : 2.71 (-4.91%)
Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE

ANVS : 2.71 (-4.91%)
Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program

ANVS : 2.71 (-4.91%)
Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

ANVS : 2.71 (-4.91%)
Annovis Bio (NYSE: ANVS) to Present at Alzheimer’s & Parkinson’s Drug Development Summit

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company focused on neurodegenerative diseases, will participate in the 13th Alzheimer’s & Parkinson’s Drug Development Summit from March...

ANVS : 2.71 (-4.91%)
Annovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment

ANVS : 2.71 (-4.91%)

Barchart Exclusives

Gold's Bull Run: Seasonal Strength Meets Conflicting COT Report—Are You In?
Gold's all-time high $3,509.9! Central banks bought big, but the COT report waves a red flag. Seasonal gains await—Market players, read or regret! Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar